Go Deep
ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,615 | -0.9 | 0.99 | 0.08 | 93.29 |
| Oct 2026 | 21,818 | -0.8 | 0.91 | 0.08 | 84.95 |
| Oct 2026 | 21,566 | -1.0 | 1.01 | 0.08 | 94.96 |
| Oct 2026 | 21,423 | -0.9 | 1.08 | 0.08 | 100.40 |
| Oct 2026 | 21,236 | -1.0 | 1.16 | 0.08 | 108.09 |
| Oct 2026 | 20,997 | -1.1 | 1.26 | 0.08 | 117.57 |
| Oct 2026 | 21,212 | -1.0 | 1.17 | 0.08 | 108.77 |
| Oct 2026 | 21,116 | -1.1 | 1.21 | 0.08 | 112.33 |
| Oct 2026 | 21,164 | -1.0 | 1.19 | 0.08 | 110.90 |
ALX Oncology Holdings Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -17,971,000.0 | -17,927,000.0 | -22,848,000.0 | -22,144,000.0 |
| EPS | -0.1 | -0.2 | -0.4 | -0.4 |
ALX Oncology Holdings Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Profit | -101,695,000.0 | -134,850,000.0 | -160,805,000.0 | -123,482,000.0 | — |
| EPS | -1.9 | -2.6 | -3.7 | -3.0 | — |
ALX Oncology Holdings Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 59,046,000.0 | 147,775,000.0 | 242,553,000.0 | 306,489,000.0 | — |
| Total Liabilities | 33,065,000.0 | 34,157,000.0 | 52,841,000.0 | 43,025,000.0 | — |
| Total Equity | 25,981,000.0 | 113,618,000.0 | 189,712,000.0 | 263,464,000.0 | — |
Owes vs Owns
ALX Oncology Holdings Inc. owed $0.15 for every $1 it owned in Jun 2026, up from $0.14 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.15× | 0.56× | 0.23× | 0.22× | 0.14× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
ALX Oncology Holdings Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 75.9%Receivables 0.5%Fixed assets (tangible) 6.6%Long-term investments 5.9%Other assets 11.2%
How it's funded — Dec 2025
Short-term debt 8.8%Long-term debt 7.7%Payables 8.3%Other liabilities 31.2%Shareholders' equity 44.0%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 44.8 | 127.8 | 182.7 | 266.2 |
| Receivables | 0.3 | 0.9 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 3.9 | 9.6 | 10.8 | 9.8 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 3.5 | 3.5 | 35.4 | 16.7 |
| Other assets | 6.6 | 6.0 | 13.6 | 13.8 |
| Liabilities & equity | ||||
| Short-term debt | 5.2 | 0.4 | 1.6 | 1.0 |
| Long-term debt | 4.5 | 9.5 | 9.6 | 9.4 |
| Payables | 4.9 | 4.5 | 8.6 | 8.1 |
| Other liabilities | 18.4 | 19.8 | 33.0 | 24.5 |
| Shareholders' equity | 26.0 | 113.6 | 189.7 | 263.5 |
| Net tangible assets | 26.0 | 113.6 | 189.7 | 263.5 |
ALX Oncology Holdings Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -84,142,000.0 | -121,912,000.0 | -130,364,000.0 | -89,223,000.0 | — |
| Investing Activities | 82,586,000.0 | 86,256,000.0 | 44,657,000.0 | -235,416,000.0 | — |
| Financing Activities | 362,000.0 | 30,817,000.0 | 59,291,000.0 | 9,860,000.0 | — |